radiotherapy or drug therapy. While medical therapy for Cushing's syndrome has been limited, several new agents are being investigated. This aim of this review is to analyze and present the ...
Zacks.com on MSN1d
Corcept Shares Rise More Than 60% in Three Months: Here's WhyShares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months against the industry’s decline ...
Pharmaceutical firm Corcept Therapeutics Incorporated (CORT) is growing the business and pleasing shareholders.
Total third-quarter revenue of $54 million was led by triple-digit percentage growth of sales of Recorlev, a cortisol ...
It’s also used as a treatment for patients with Cushing’s syndrome and is being tested as a treatment for other diseases. And new research published this week found that the drug could also ...
Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and immunology, today announced that the Phase ...
This medication is teratogenic and is not currently approved for use in the treatment of Cushing's syndrome. [51] ACTH: Adrenocorticotrophic hormone; b.i.d.: Twice daily; GI: Gastrointestinal ...
PORTLAND, Ore.--(BUSINESS WIRE)--Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback